Randomized, Vehicle-controlled Trials of Topical 5-fluorouracil Therapy for Actinic Keratosis Treatment

An Overview

Maral Rahvar; Sonia A Lamel; Howard I Maibach


Immunotherapy. 2012;4(9):939-945. 

In This Article


Different surgical and nonsurgical methods are available for AK treatment with patient medical status, lesion number and characteristics, prior treatment, and anatomic location often guiding management decisions.[19] The antineoplastic drug, 5-fluorouracil (5-FU), was first noted for its usefulness in the treatment of AKs in 1962 when patients taking it as a systemic chemotherapy had a subsequent disappearance of their AKs.[20] This led to US FDA approval of topical 5-FU for AK treatment in the 1970s and subsequent development of multiple formulations.[21] It is more useful in the setting of multiple lesions when destructive therapies such as cryosurgery are less helpful.[18]